Cargando…

Albiglutide, a Long Lasting Glucagon-Like Peptide-1 Analog, Protects the Rat Heart against Ischemia/Reperfusion Injury: Evidence for Improving Cardiac Metabolic Efficiency

BACKGROUND: The cardioprotective effects of glucagon-like peptide-1 (GLP-1) and analogs have been previously reported. We tested the hypothesis that albiglutide, a novel long half-life analog of GLP-1, may protect the heart against I/R injury by increasing carbohydrate utilization and improving card...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bao, Weike, Aravindhan, Karpagam, Alsaid, Hasan, Chendrimada, Thimmaiah, Szapacs, Matthew, Citerone, David R., Harpel, Mark R., Willette, Robert N., Lepore, John J., Jucker, Beat M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162574/ https://www.ncbi.nlm.nih.gov/pubmed/21887274 http://dx.doi.org/10.1371/journal.pone.0023570

Ejemplares similares

Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart
por: Aravindhan, Karpagam, et al.
Publicado: (2015)

Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat
por: Bao, Weike, et al.
Publicado: (2013)

Generalized Edema Caused by Albiglutide: A Case Report
por: Aziz, Kashif, et al.
Publicado: (2018)

Once-weekly albiglutide in the management of type 2 diabetes: patient considerations
por: Woodward, Heather N, et al.
Publicado: (2014)

Quantitative Testing of Prescriber Knowledge Regarding the Risks and Safe Use of Albiglutide
por: Koro, Carol, et al.
Publicado: (2017)

Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study
por: Darpo, Borje, et al.
Publicado: (2014)

Erratum to: Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study
por: Darpo, Borje, et al.
Publicado: (2014)

Weekly glucagon‐like peptide‐1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double‐blind, placebo‐controlled study
por: Nino, Antonio, et al.
Publicado: (2017)

Cardioprotection by systemic dosing of thymosin beta four following ischemic myocardial injury
por: Bao, Weike, et al.
Publicado: (2013)

High FGF23 Levels Failed to Predict Cardiac Hypertrophy in Animal Models of Hyperphosphatemia and Chronic Renal Failure
por: Moench, Ian, et al.
Publicado: (2021)

Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial
por: Rosenstock, Julio, et al.
Publicado: (2020)

An indirect comparison of HbA(1c) treatment effect with albiglutide and exenatide 2.0 mg QW using the Bucher method
por: Martin, Alan A, et al.
Publicado: (2016)

Effects of six pyrimidine analogs on the growth of Tetrahymena thermophila and their implications in pyrimidine metabolism
por: Harpel, Zander, et al.
Publicado: (2023)

A glucagon analog chemically stabilized for immediate treatment of life-threatening hypoglycemia()
por: Chabenne, Joseph, et al.
Publicado: (2014)

Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity
por: Yazıcı, Dilek, et al.
Publicado: (2022)

Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing
por: Rosenstock, Julio, et al.
Publicado: (2009)

Newer Vistas in Glucagon-Like Peptide-1 Analog Therapy - Marvels of Peptide Engineering
por: Jacob, Jubbin Jagan, et al.
Publicado: (2021)

Parathyroid Hormone-Related Peptide and Its Analog, Abaloparatide, Attenuate Lethal Myocardial Ischemia-Reperfusion Injury
por: Wider, Joseph, et al.
Publicado: (2022)

Engineered Cardiac Tissues Generated in the Biowire II: A Platform for Human-Based Drug Discovery
por: Feric, Nicole T, et al.
Publicado: (2019)

Discrepancy between the Actions of Glucagon-like Peptide-1 Receptor Ligands in the Protection of the Heart against Ischemia Reperfusion Injury
por: Ismaeil, Ali, et al.
Publicado: (2022)

Apelin-12 and its structural analog enhance antioxidant defense in experimental myocardial ischemia and reperfusion
por: Pisarenko, O. I., et al.
Publicado: (2014)

Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits
por: Ebdrup, Bjørn H, et al.
Publicado: (2012)

Glucagon-like Peptide-1 (GLP-1) Analogs: Recent Advances, New Possibilities, and Therapeutic Implications
por: Manandhar, Bikash, et al.
Publicado: (2014)

Glucagon-Like Peptide-1 Analog, Liraglutide, Delays Onset of Experimental Autoimmune Encephalitis in Lewis Rats
por: DellaValle, Brian, et al.
Publicado: (2016)

Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review
por: Teshome, Getnet, et al.
Publicado: (2020)

An updated overview of glucagon-like peptide-2 analog trophic therapy for short bowel syndrome in adults
por: Zhu, Changzhen, et al.
Publicado: (2022)

Chronic Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 Activity Decreases Hypertension, Insulin Resistance, and Hypertriglyceridemia in Metabolic Syndrome
por: Schnackenberg, Christine G., et al.
Publicado: (2013)

Pregnant Women Sharing Pregnancy-Related Information on Facebook: Web-Based Survey Study
por: Harpel, Tammy
Publicado: (2018)

Glucagon and exenatide improve contractile recovery following ischaemia/reperfusion in the isolated perfused rat heart
por: Lindsay, Ross T., et al.
Publicado: (2023)

Stabilization of postprandial blood glucose fluctuations by addition of glucagon like polypeptide-analog administration to intensive insulin therapy
por: Ogawa, Susumu, et al.
Publicado: (2015)

Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats
por: Zhou, Xiaoyan, et al.
Publicado: (2015)

Glucagon-like peptide-1 analog liraglutide leads to multiple metabolic alterations in diet-induced obese mice
por: Park, Seokjae, et al.
Publicado: (2022)

Glucagon Receptor Signaling and Glucagon Resistance
por: Janah, Lina, et al.
Publicado: (2019)

Enzymatic mono-pegylation of glucagon-like peptide 1 towards long lasting treatment of type 2 diabetes
por: Selis, Fabio, et al.
Publicado: (2012)

Protective Effect of a GLP-1 Analog on Ischemia-Reperfusion Induced Blood–Retinal Barrier Breakdown and Inflammation
por: Gonçalves, Andreia, et al.
Publicado: (2016)

Hepatic ischemia-reperfusion syndrome and its effect on the cardiovascular system: The role of treprostinil, a synthetic prostacyclin analog
por: Mouratidou, Christina, et al.
Publicado: (2023)

HUMAN PLASMA ALPHA 2-MACROGLOBULIN : AN INHIBITOR OF PLASMA KALLIKREIN
por: Harpel, Peter C.
Publicado: (1970)

STUDIES ON HUMAN PLASMA α(2)-MACROGLOBULIN-ENZYME INTERACTIONS : EVIDENCE FOR PROTEOLYTIC MODIFICATION OF THE SUBUNIT CHAIN STRUCTURE
por: Harpel, Peter C.
Publicado: (1973)

Long-Lasting Exendin-4-Loaded PLGA Nanoparticles Ameliorate Cerebral Ischemia/Reperfusion Damage in Diabetic Rats
por: Chung, Cheng-Hsun, et al.
Publicado: (2022)

Glucagon-Like Peptide-1 Analog Liraglutide Protects against Diabetic Cardiomyopathy by the Inhibition of the Endoplasmic Reticulum Stress Pathway
por: Liu, Jieyu, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_pnpdpu4m4vctrkk4hj00qr64jh